ZL0420

ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain

Research Areas >> Inflammation/Immunology

IC50: 27 nM (BRD4 BD1), 32 nM (BRD4 BD2)[1]

ZL0420 is well docked into the acetyl-lysine (KAc) binding pocket of BRD4, forming key interactions including the critical hydrogen bonds with Asn140 directly and Tyr97 indirectly via a H2O molecule. ZL0420 exhibits submicromolar potency of inhibiting the TLR3-dependent innate immune gene program, including ISG54, ISG56, IL-8, and Groβ genes in cultured human small airway epithelial cells (hSAECs) with IC50s of 0.49-0.86 µM[1].

ZL0420 demonstrates potent efficacy reducing airway inflammation in a mouse model with low toxicity. ZL0420 displays high efficacy and almost completely blocks the profound accumulation of neutrophils around the small and medium sized airways induced by poly(I:C) administration[1].

hSAECs are first pretreated with a series final concentrations of BRD4 inhibitors from 0.01 nM to 100 µM for 24 hours and are then added poly(I:C) at 10 µg/mL for another 4 hours prior to harvesting the cells. The harvested cells are first ished with PBS twice and then the total RNA is extracted using acid guanidinium phenol extraction. The total RNA is further reverse-transcribed for gene expression analysis by Q-RT-PCR[1].

Mice[1] C57BL/6 mice are pre-treated in the absence or presence of the ZL0420 [10 mg/kg body weight, via the intraperitoneal route] one day prior to poly(I:C) stimulation. The next day, animals are given another dose of ZL0420 immediately followed by intranasal (i.n.) administration of phosphate-buffered saline (PBS, 50 µL) or poly(I:C) (300 µg dissolved in 50 µL PBS). One day later, the mice are euthanized. The bronchoalveolar lavage fluid (BALF) and lung tissues of treated mice are collected for further analysis[1].

[1]. Liu Z, et al. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur J Med Chem. 2018 May 10;151:450-461.

(+)-JQ1 | GSK126 | Tazemetostat (EPZ-6438) | Birabresib (OTX015) | A 485 | Curcumin | ARV-771 | ARV-825 | I-BET762 | BI 2536 | GSK343 | C646 | 3-Deazaneplanocin A (hydrochloride) | I-BET151 | 666-15